Trimethoprim-Sulfamethoxazole plus Amikacin versus Ceftazidime Monotherapy as Empirical Treatment in Patients with Neutropenia and Fever

References

• Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Mayers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, You MD. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J infect Dis 1990; 161: 381–396
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061–1065
   PubMed Web of Science ®Google Scholar
• Pizzo P. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323–1332
   PubMed Web of Science ®Google Scholar
• Pizzo P, Hathorn J, Heimenz J, Browne M, Commers J, Cotton D, Gress J, Long D, Marshall D, McKnight J, Rubin M, Skeleton J, Thaler M, Wesley R. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558
   PubMed Web of Science ®Google Scholar
• Sanders JW, Powe NR, Moor RD. Ceftazidime monotherapy for empiric treatment of neutropenic patients: a metaanalysis. J Infect Dis 1991; 164: 907–916
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Johi JH, Keating MJ, Holms FA, Cabanillas FF, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283–291
   PubMed Web of Science ®Google Scholar
• De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P. Cefazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834–844
   PubMed Web of Science ®Google Scholar
• Engervall P, Stiernstedt G, Günther G, Björkholm M. Trimethoprim-sulfamethoxazole plus amikacin as first empirical therapy and imipenem/cilastatin as secondary therapy in febrile neutropenic patients with hematological disorders. J Chemotherapy 1992; 4: 99–106
   PubMed Web of Science ®Google Scholar
• Young LS, Hindler J. Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients. Rev Infect Dis 1987; 9: 177–181
   Google Scholar
• Stuart R, Braine H, Lietman P, Saral R, Fuller D. Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients: a prospective, randomized, double-blind study. Am J Med 1980; 86: 876–885
   Google Scholar
• Bodey GP, Grose A WE, Keating MJ. Use of trimethoprimsulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 1982; 4: 579–585
   PubMedGoogle Scholar
• Braine HG, Stuart RK, Saral R, Lietman PS. Parenteral trimethoprim-sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis 1982; 4: 586–592
   PubMedGoogle Scholar
• Günther G, Björklind A, Engervall P, Björkholm M, Stiernstedt G. Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile. Scand J Infect Dis 1991; 23: 589–598
   PubMed Web of Science ®Google Scholar
• Samuelson J, Lönnqvist B, Palmblad J, Grimfors G, Järnmark M, Lerner R, Ljungman P, Nyström-Rosander C, Öberg G. Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Scand J Infect Dis 1992; 24: 89–96
   PubMedGoogle Scholar
• Axdorph U, Laurell G, Björkholm M. Monitoring of hearing during treatment of leukemia with special reference to the use of amikacin. J Intern Med 1993; 233: 401–407
   PubMed Web of Science ®Google Scholar
• Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397–401
   PubMed Web of Science ®Google Scholar
• The EORTC International Antimicrobial Therapy Project Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–1698
   PubMed Web of Science ®Google Scholar
• De Jongh CA, Joshi JH, Thompson BW, Newman KA, Finley RS, Moody MR, Salatore PC, Tenney JH, Drusano GL, Schimpff SC. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1986; 80: 101–111
   PubMed Web of Science ®Google Scholar
• Menichelli F, Del Favero A. The role of Gram-positive therapy in the neulropenic patient. J Antimicrob Chemother 1991; 27: 51–60
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada – Clinical Trials Group. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951–958
   PubMed Web of Science ®Google Scholar
• Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone J-D, Rand KH, Giliom M, Shands JW, Jr., Kramer BS. Vancomycin is not essential component of the initial empirical treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 1062–1067
   PubMed Web of Science ®Google Scholar
• De Jongh CA, Johshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC. Antibiotic synergism and response in gram-negative bacteraemia in granulocytopenic cancer patients. Am J Med 1986; 80: 96–111
   PubMed Web of Science ®Google Scholar
• Golde DW, Bersch N, Quan SC. Trimethoprim and sulfamethoxazole inhibition of haematopoiesis in vitro. Br J Haematol 1978; 40: 363–367
   PubMed Web of Science ®Google Scholar
• Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect 1990; 15: 49–53
   PubMed Web of Science ®Google Scholar
• Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, Fabbri A, Secondo V, Terragna A. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991; 13: 397–404
   PubMedGoogle Scholar
• Goldstein FW, Coutrot A, Sieffer A, Acar JF. Percentage and distributions of telcoplanin -and vancomycin-resistant stains among coagulase-negative staphylococci. Antimicrobial Agents Chemother 1990; 34: 899–900
   PubMed Web of Science ®Google Scholar
• Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316: 927–931
   PubMed Web of Science ®Google Scholar
• Fredlund H, Björeman M, Kjellander J, Sjöberg L, Bjorne L, Öhlin A-L. A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital. Scand J Infect Dis 1990; 22: 381–391
   PubMed Web of Science ®Google Scholar